Histogen Inc.
HSTO · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | -1,223.18% | -789.99% | -493.34% | -915.49% |
| EV / EBITDA | 1.14 | 1.19 | 1.33 | 2.46 |
| Quality | ||||
| ROIC | -78.88% | -16.25% | -23.20% | -16.41% |
| Gross Margin | -1,140.00% | -660.00% | -660.00% | -850.00% |
| Cash Conversion Ratio | 0.70 | 1.15 | 0.73 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | -76.10% | -75.53% | -76.14% | 22.33% |
| Free Cash Flow Growth | -12.23% | 6.04% | -4.51% | 0.77% |
| Safety | ||||
| Net Debt / EBITDA | 1.19 | 1.34 | 1.48 | 2.55 |
| Interest Coverage | 0.00 | -2,088.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -560.32 | -933.16 | -630.47 | 1,322.76 |